AdvaMed To FDA: IRB Uncertainty, Trial Recruiting Hamper CoA Studies
This article was originally published in The Gray Sheet
Executive Summary
Institutional review board confusion over FDA condition-of-approval (CoA) study requirements is a barrier to completing such studies, according to AdvaMed
You may also be interested in...
Survey Shows Gaps In CoA Monitoring; FDA Sees Guidance, Tracking As Fixes
FDA says it is monitoring newly implemented measures aimed at bolstering design, execution and completion of Condition of Approval (CoA) studies
Firms To Be Held More Accountable For Completing Postmarket Studies – FDA
FDA plans to shift the tracking of postmarket studies from the Office of Device Evaluation to the Office of Surveillance & Biometrics by year-end to enable ODE to better meet MDUFMA goals
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.